Abstract:Background: Deoxyribonuclease 1 like 3 (DNASE1L3) is a secreted enzyme that has been shown to digest the extracellular chromatin derived from apoptotic bodies, and DNASE1L3 pathogenic variants have been associated with a lupus phenotype. It is unclear whether interferon signaling is sustained in DNASE1L3 deficiency in humans. Objectives: To explore interferon signaling in DNASE1L3 deficient patients. To depict the characteristic features of DNASE1L3 deficiencies in human. Methods: We identified, characterized, and analyzed five new patients carrying biallelic DNASE1L3 variations. Whole or targeted exome and/or Sanger sequencing was performed to detect pathogenic variations in five juvenile systemic erythematosus lupus (jSLE) patients. We measured interferon-stimulated gene (ISG) expression in all patients. We performed a systematic review of all published cases available from its first description in 2011 to March 24th 2022. Results: We identified five new patients carrying biallelic DNASE1L3 pathogenic variations, including three previously unreported mutations. Contrary to canonical type I interferonopathies, we noticed a transient increase of ISGs in blood, which returned to normal with disease remission. Disease in one patient was characterized by lupus nephritis and skin lesions, while four others exhibited hypocomplementemic urticarial vasculitis syndrome. The fourth patient presented also with early-onset inflammatory bowel disease. Reviewing previous reports, we identified 35 additional patients with DNASE1L3 deficiency which was associated with a significant risk of lupus nephritis and a poor outcome together with the presence of anti-neutrophil cytoplasmic antibodies (ANCA). Lung lesions were reported in 6/35 patients. Conclusions: DNASE1L3 deficiencies are associated with a broad phenotype including frequently lupus nephritis and hypocomplementemic urticarial vasculitis with positive ANCA and rarely, alveolar hemorrhages and inflammatory bowel disease. This report shows that interferon production is transient contrary to anomalies of intracellular DNA sensing and signaling observed in Aicardi-Goutières syndrome or STING-associated vasculitis in infancy (SAVI).

cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing

Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency

ARF1 prevents aberrant type I interferon induction by regulating STING activation and recycling

Deficiency for SAMHD1 activates MDA5 in a cGAS/STING-dependent manner

Enhanced cGAS-STING-dependent interferon signaling associated with mutations in ATAD3A

Regulation of cGAS-STING Pathway - Implications for Systemic Lupus Erythematosus

deficiency triggers autoinflammation via cGAS-STING activation

Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation

Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review

Novel interferonopathies associated with mutations in RIG-I like receptors

DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling

Genome instability independent of type I interferon signaling drives neuropathology caused by impaired ribonucleotide excision repair

The prototypical interferonopathy: Aicardi‐Goutières syndrome from bedside to bench

cGAS surveillance of micronuclei links genome instability to innate immunity

A sensitive assay for measuring whole-blood responses to type I IFNs

Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus

A Novel Homozygous Y140X Mutation of ISG15 Causes Diverse Type I Interferonopathies in Sibling Patients with Cutaneous Lesions or Recurrent Parenchymal Pneumonia.

DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis

Nuclear cGAS Functions Non-canonically to Enhance Antiviral Immunity via Recruiting Methyltransferase Prmt5

Interferon target-gene expression and epigenomic signatures in health and disease

Type I interferon signaling and peroxisomal dysfunction contribute to enhanced inflammatory cytokine production in Irgm1-deficient macrophages